HLB bioStep Non-Registered Executive Lee Hyeong-seok Acquires 3,000 Common Shares via Open Market Purchase, Increasing Stake to 0.02% - Minimal Impact on Stock Price

HLB bioStep's non-registered executive managing director Lee Hyeong-seok purchased 3,000 common shares through an open market transaction on June 4, 2026.
The acquisition price was 3,160 KRW per share, raising his ownership from 0% to 0.02% of total outstanding shares.
This small-scale personal investment amounts to only 0.02% of the total 17,432,396 outstanding shares and is unlikely to materially affect the company's financial structure or stock price. However, insider buying may be interpreted as a positive signal of management confidence.
[AI Summary]HLB bioStep insider Lee Hyeong-seok bought 3,000 common shares, but his stake is a negligible 0.02% with no direct shareholder value impact. The small purchase offers only a mild confidence signal with limited effect on stock price or enterprise value.